Perspectives: Exploring the Telehealth Extension: Building Infrastructures for Better Access

TTA has an open invitation to industry leaders to contribute to our Perspectives non-promotional opinion and thought leadership area. Today’s topic is on how the most recent two-year extension of Medicare telehealth flexibilities necessitate a more robust healthcare infrastructure to better utilize the additional data generated by remote patient monitoring. The author, Jiang Li, Ph.D., is founder and CEO of Vivalink, Inc., a Silicon Valley company developing digital health technology solutions for remote patient monitoring in healthcare and clinical research.

Ensuring equal healthcare access to Americans across the country is an ongoing effort. The latest funding bill from Congress looks to improve access by expanding where and how people receive care through a two-year extension of Medicare telehealth flexibilities. The bill adds to the five-year extension to the CMS Acute Hospital Care at Home (AHCAH) waiver, which allows hospitals to deliver acute inpatient care in patients’ homes with full Medicare reimbursement. Since its launch in 2020, the program has continued to receive extensions in the continued effort to ensure Americans living in rural or remote areas receive the healthcare they need.

Under the current Medicare extensions, telehealth provides real-time medical and mental health appointments over secure video from a patient’s location, along with a wide range of Part B services such as specialist consults, rehab, and psychotherapy. This latest extension allows beneficiaries to continue receiving this care from an expanded list of healthcare providers. While the original waiver was authorized in response to COVID-19, research shows that around 17% of healthcare visits were conducted via telehealth modalities post-2020, with over 116 million global users listed in 2024.

Telehealth helps address a gap in healthcare access felt by many Americans living in rural locations. While the extension provides flexibility for those patients to continue receiving remote care, it isn’t enough to close the gaps in American healthcare on its own. What will define its success is a deliberate investment in infrastructure from health systems, policymakers, and technology developers alike.

Exploring the Access Problem

Nearly 80% of rural America is classified as medically underserved, facing barriers such as provider shortages, high poverty rates, and a rapidly aging population. For Medicare-eligible patients in these communities, the obstacles to consistent care, including transportation limitations to caregiver responsibilities, can often prove to be insurmountable, blocking them from necessary medical care.

We see the direct result of these consequences in the data. One significant example is cardiac rehabilitation — more than one million Americans become eligible each year, yet fewer than 20% participate. Even among those referred, less than 34% enroll, largely because the model still demands repeated clinic visits that many patients simply cannot manage. This has been a slow but sure systemic struggle, embedded in how care has historically been designed and delivered.

We can see these consequences further compounded by issues with traditional monitoring. Episodic, in-clinic measurements offer only brief snapshots of a patient’s health, often missing transient but dangerous events occurring between visits. A study at Brigham and Women’s Hospital found that 27% of cardiac surgery patients experienced new atrial fibrillation episodes after discharge that traditional follow-up would have missed entirely. This post-discharge period, long treated as a clinical blind spot, illustrates the value of supporting remote care.

Making Changes for a Stronger Infrastructure

The outcomes of the AHCAH waiver have been significant: an analysis of over 5,800 patients treated under the waiver at Mass General Brigham found in-care mortality below 1%, compared to a national inpatient average of approximately 2%, with only 7% requiring return hospitalization. The cost savings are notable as well, with one review finding that hospital-at-home (HaH) patients cost approximately 20% less than traditional inpatients, allowing Medicare to spend $1,000 to $3,300 less per case across common conditions like pneumonia, heart failure, and sepsis in the 30 days post-discharge.

To ensure similar outcomes and savings at scale, a stronger infrastructure is needed. We’re already seeing movement in the replacement of traditional, episodic data by medical-grade wearable sensors capable of continuous ECG monitoring, temperature tracking, and real-time data transmission. We’re already seeing solutions for issues such as interrupted data capture during connectivity gaps, simply by expanding the storage capabilities of devices that support rural Medicare populations.

Interoperability is equally important. Biometric data from wearables should flow directly into electronic health records and centralized clinical dashboards, delivering real-time alerts without burdening staff with manual data entry. For regional and mid-sized hospitals that serve the most underserved populations, this means access to modular platforms rather than expensive third-party bundles that absorb reimbursements before they reach patient care.

Supporting a Stronger Future

The decision to extend Medicare telehealth flexibilities is a market signal for health systems. Regulatory uncertainty has been one of the greatest barriers to the advancement of remote patient monitoring platforms, wearable infrastructure, and other programs. When reimbursement timelines are measured in months, it is difficult to justify multi-year infrastructure investments. As the CMS update extends reimbursement by two years, at-home care now has the opportunity to become an evolving standard of Medicare delivery worth investing in.

The opportunity extends well beyond Medicare. The same remote patient monitoring infrastructure enabling home-based acute care is powering decentralized clinical trials, expanding access for older and rural patients historically excluded from research. These opportunities for growth and inclusivity, supported by CMS, signal that at-home care is becoming a permanent feature of how Medicare is delivered.

Short takes: Owlet’s baby sleep survey, MediBioSense’s Infinity Watch, telehealth extensions move to Senate, EBG’s telemental laws app ’26 update, Done Global indicted with principals convicted

Rounding up some current–and back–stories:

The January season for reports continues with Owlet’s newly released ‘Baby Sleep Report’. This surveyed data was generated via Owlet devices (Dream Sock, Dream Duo, and Dream Sight) from 1.2 million babies over 900 million hours of monitoring in 200 different geographic regions during 2025. The survey purpose was to research sleep patterns, trends, and developments affecting babies monitored from one to 18 months. One major finding was that baby night awakenings, that bane of life for nearly all parents, drop by 55% by about 9 months, and sleep patterns stabilize in the first six months. Other findings summarized in the release:

  • 80% of bedtime changes happen in the first six months
  • By 6–8 months, babies on average sleep nearly nine hours at a time
  • Biggest sleep and pulse rate changes happen in the first two months
  • Early high pulse rates are common and usually reflect age-typical patterns
  • Pulse rate remains higher during light sleep than deep sleep

The full report is available here.  

Doncaster, UK’s MediBioSense will be introducing in March the MBS Infinity Watch, which combines an Android-based smartwatch, smartphone, and medical wearable. We covered MBS and the CEO/founder Simon Beniston back in 2018 (!) when your Editor was doing consulting for an app security company partnering with MBS’ on their first product, VitalPatch. MBS products such as the VitalPatch are distributed in the UK, Europe, Saudi Arabia, South America, and Australia. Mr. Beniston’s latest update is on his LinkedIn post. An earlier update from Business Doncaster, a local publication, was published in October. They also achieved medical certification from the Saudi FDA (SFDA) for VitalPatch after a rigorous two-year (and nine month!) process.

The US House voted on Thursday’s (22 Jan) to send a ‘minibus’ bill containing several long-fought for telehealth extension/expansion provisions to the Senate. A ‘minibus’ combines several funding bills (versus a massive ‘omnibus’) in a multi-bill FY26 funding package released by the House Appropriations Committee earlier this week. With legislation related to the Departments of Labor, the Departments of Health and Human Services (HHS), Education, Defense, and Transportation, it contains key provisions preserving telehealth including those not included in last year’s One Big Beautiful Bill Act. They are:

  • Extension of Medicare telehealth flexibilities through December 31, 2027.
  • Five-year extension of the Acute Hospital Care at Home Program through September 30, 2030.
  • Extension of in-home cardiopulmonary rehabilitation flexibilities through January 1, 2028.
  • Enhancements to certain durable medical equipment (DME) requirements under Medicare.
  • Requirement that HHS issue guidance within one year on furnishing telehealth services to individuals with limited English proficiency.
  • Inclusion of virtual diabetes suppliers in the Medicare Diabetes Prevention Program through December 31, 2029.

The American Telemedicine Association and ATA Action continue to track and lobby for the extensions. Release 20 Jan, 22 Jan.

Digital health law firm Epstein Becker Green (EBG) announced an update to their free Telemental Health Laws app. The app, available on the Apple App Store and Google Play, is a reference for state-specific laws and policies governing telehealth. This year’s issues include shifting Medicare rules, the gray areas of remote prescribing, and escalating compliance requirements. There’s also the continuing drama of the DEA’s kicking the can down the road, extending pandemic-era prescribing flexibilities to the end of the year versus finalizing a permanent framework for remote prescribing of controlled substances. EBG’s page with link to the app

Last, but not least, are the substantial Federal prison terms that teleprescriber Done Global’s two principals will be facing come 25 February–followed by the indictment of the company. Both founder/CEO Ruthia He and clinical president David Brody were convicted of six counts of illegal distribution of Adderall, a controlled substance, via Done’s telehealth operation, and the submission of false and fraudulent claims for reimbursement for Adderall and other stimulants. The cost? $100 million, as well as “clients’ substance abuse, addiction and, in some cases, overdose”. The fraud included deceptive social media, paying nurse practitioners to refill prescriptions without interaction, and auto-refilling. Both He and Brody were convicted by jury in November. The indictments date back to June 2024 [TTA 24 June, 3 July] and was the first Federal prosecution of criminal drug distribution related to telemedicine prescribing by a digital health company. In December, a Federal grand jury also returned an indictment against Done Global and Mindful Mental Wellness P.A. (MMW), a Florida company, for conspiracy to provide Done members with prescriptions for Adderall and other stimulants that were not issued for a legitimate medical purpose, in return for a subscription fee. Done Global is charged with prescribing over 40 million pills of Adderall and other stimulants, and fraud of $100 million in revenue. Both trials and indictments are in San Francisco, Federal Northern District of California. Department of Justice releases 19 Nov, 17 Dec 2025.